Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial
 

News Releases

Click here to sign up and receive email notifications of new press releases.

June 13, 2017
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1
June 08, 2017
Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
May 23, 2017
Asterias Biotherapeutics Announces Top Leadership Transition
May 11, 2017
Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
May 11, 2017
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
May 04, 2017
Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
May 03, 2017
Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
April 26, 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
April 25, 2017
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury
March 28, 2017
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
March 21, 2017
Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
March 07, 2017
Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
February 03, 2017
Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
January 24, 2017
Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
January 18, 2017
Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
January 09, 2017
Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
November 17, 2016
Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics
November 14, 2016
Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study
November 08, 2016
Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
November 04, 2016
Asterias Biotherapeutics to Report Third Quarter Results on November 14, 2016
September 27, 2016
Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population
September 14, 2016
Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1
September 13, 2016
Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016
September 12, 2016
Asterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September 12, 2016, in Advance of Upcoming Interim Efficacy Data Release from Spinal Cord Injury Trial
September 07, 2016
Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients to be Presented at the 55th ISCoS Annual Scientific Meeting
August 31, 2016
Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
August 15, 2016
Asterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST-OPC1 in Spinal Cord Injury Patients
August 01, 2016
Asterias Biotherapeutics to Report Second Quarter Results on August 15, 2016
July 18, 2016
Asterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel
July 12, 2016
Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury
June 21, 2016
Asterias Biotherapeutics Announces Oral Presentation and Participation in Panel Discussion at the ISSCR 14th Annual Meeting
May 24, 2016
Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1
May 23, 2016
Asterias Biotherapeutics Closes Exercise of Over-Allotment Option in Connection with its Previously Announced Public Offering
May 16, 2016
Asterias Biotherapeutics Reports First Quarter Results
May 13, 2016
Asterias Biotherapeutics Announces Closing of Public Offering of Common Stock and Warrants, and Exercise of Over-Allotment Option to Purchase Additional Warrants
May 11, 2016
Asterias Biotherapeutics to Report First Quarter Results on May 16, 2016
May 10, 2016
Asterias Biotherapeutics Prices Public Offering of Common Stock and Warrants
May 09, 2016
Asterias Biotherapeutics Announces Proposed Public Offering
May 02, 2016
Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting
April 28, 2016
Howard I. Scher M.D., Leading Clinical Oncology Expert, Joins the Board of Directors of Asterias Biotherapeutics
April 26, 2016
Asterias Biotherapeutics to Present at Stem Cell Summit 2016
March 31, 2016
Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to Holders of Asterias Series A Common Stock
March 29, 2016
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Reviews the Company's Three Clinical-Stage Cell Therapy Programs
March 23, 2016
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2015 Results on March 29, 2016
February 29, 2016
Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer
February 24, 2016
Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1
February 16, 2016
Asterias Biotherapeutics Announces Intention to Distribute 3.15 Million Warrants to Purchase Common Shares of Asterias to Asterias Shareholders
February 04, 2016
Asterias Biotherapeutics Receives Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
February 02, 2016
Asterias Biotherapeutics to Present at the 18th Annual BIO CEO & Investor Conference
January 21, 2016
Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial
January 06, 2016
Asterias Biotherapeutics to Present at Biotech Showcase™ 2016
November 09, 2015
Asterias Biotherapeutics Reports Third Quarter Results
November 05, 2015
Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015
November 02, 2015
Georgia Erbez Appointed Chief Financial Officer Of Asterias Biotherapeutics
October 20, 2015
Asterias Biotherapeutics to Begin Dose Escalation in the SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
October 13, 2015
Asterias Biotherapeutics Announces Collaboration with Cell Therapy Catapult to Scale Production of AST-VAC2
October 12, 2015
Asterias Biotherapeutics to Participate in Webcast on Innovations in Regenerative Medicine & Curative Biologics
October 05, 2015
Asterias Biotherapeutics to Present at 2015 Stem Cell Meeting on the Mesa
September 09, 2015
Asterias Biotherapeutics Announces Publication of Preclinical Data that Supports the Safety and Use of AST-OPC1 as a Treatment for Spinal Cord Injury (SCI)
August 31, 2015
Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
August 27, 2015
Asterias Biotherapeutics to Present at Upcoming Investor Conferences
August 10, 2015
Asterias Biotherapeutics Reports Second Quarter Results
July 29, 2015
Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015
June 30, 2015
Asterias Biotherapeutics Added To Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® Indexes
June 15, 2015
Preliminary Reconstitutions of Russell 3000®, Russell Global and Russell Microcap® Indexes Include Asterias Biotherapeutics
June 08, 2015
Asterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
June 01, 2015
Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics’ AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
May 26, 2015
Asterias Biotherapeutics Receives $11.7 Million in Proceedsfrom Exercise of Warrants
May 14, 2015
Asterias Biotherapeutics Announces Availability of Abstract with Phase 2 Clinical Data on Cancer Vaccine AST-VAC1 in Acute Myelogenous Leukemia (AML)
May 07, 2015
Asterias Biotherapeutics Promotes Edward Wirth, M.D., Ph.D. to Chief Medical Officer
May 07, 2015
Asterias Biotherapeutics Reports First Quarter Results
May 06, 2015
Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury
April 30, 2015
Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015
April 21, 2015
Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting
April 09, 2015
Asterias Biotherapeutics Announces Change to Presentation Time at Needham Healthcare Conference
April 06, 2015
Asterias Biotherapeutics to Present at Needham Healthcare Conference
March 18, 2015
Asterias Biotherapeutics to Present at Regen Med Investor Day 2015
March 10, 2015
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2014 Financial and Operating Results
March 05, 2015
Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury
March 04, 2015
Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange
March 02, 2015
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015
February 10, 2015
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
February 05, 2015
Asterias Biotherapeutics Prices Public Offering of Common Stock
February 04, 2015
Asterias Biotherapeutics Announces Public Offering of Common Stock
January 07, 2015
Asterias Biotherapeutics to Present at Biotech Showcase™ 2015
November 18, 2014
Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference
November 17, 2014
Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury
November 10, 2014
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results
October 31, 2014
Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014
October 20, 2014
Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury
October 06, 2014
Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT
September 29, 2014
Asterias Biotherapeutics Announces Distribution Date of BioTime Warrants and Conversion Date of Series B Common Stock into Series A Common Stock
September 11, 2014
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer
September 04, 2014
Asterias Biotherapeutics Announces Record Date for Distribution of BioTime Warrants to Holders of Asterias Series A Common Stock
August 27, 2014
Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury
August 25, 2014
Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
August 21, 2014
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
July 24, 2014
Asterias Biotherapeutics Announces Live Investor Webcast
June 17, 2014
BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing
June 17, 2014
BioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO
June 12, 2014
BioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer
May 30, 2014
BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine
May 28, 2014
BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
May 22, 2014
Asterias Biotherapeutics, Inc. Announces New Results from First-in-Man Clinical Trial of a Cell Therapy Derived from Embryonic Stem Cells
May 21, 2014
Asterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com
May 13, 2014
Asterias Biotherapeutics, Inc. to Present Phase 1 Clinical Data at the 17th Annual Meeting of the American Society of Gene & Cell Therapy
January 02, 2014
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing
December 02, 2013
Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
October 28, 2013
Asterias Biotherapeutics, Inc. Plans to File Registration Statement for Underwritten Public Offering
October 01, 2013
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
January 07, 2013
BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets
November 15, 2012
BioTime and BioTime Acquisition Corporation Announce Combined $10 Million Financing
November 15, 2012
BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
October 18, 2012
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation
September 28, 2012
BioTime Forms BioTime Acquisition Corporation


Investor Relations
InvestorRelations@asteriasbio.com
Tel: (510) 456-3892

Media Relations
News@asteriasbio.com

Medical Information
MedicalInquiries@asteriasbio.com

About Asterias | Trials | Contact
Asterias Biotherapeutics Tel: (510) 456-3800